- Home
- TMQ vs FDMT Comparison
TMQ vs FDMT Comparison
Compare TMQ & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMQ
- FDMT
- Stock Information
- Founded
- TMQ 2004
- FDMT 2013
- Country
- TMQ Canada
- FDMT United States
- Employees
- TMQ N/A
- FDMT N/A
- Industry
- TMQ Precious Metals
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- TMQ Basic Materials
- FDMT Health Care
- Exchange
- TMQ Nasdaq
- FDMT Nasdaq
- Market Cap
- TMQ 226.7M
- FDMT 192.2M
- IPO Year
- TMQ N/A
- FDMT 2020
- Fundamental
- Price
- TMQ $1.89
- FDMT $4.16
- Analyst Decision
- TMQ
- FDMT Buy
- Analyst Count
- TMQ 0
- FDMT 10
- Target Price
- TMQ N/A
- FDMT $32.33
- AVG Volume (30 Days)
- TMQ 613.8K
- FDMT 391.3K
- Earning Date
- TMQ 07-10-2025
- FDMT 08-07-2025
- Dividend Yield
- TMQ N/A
- FDMT N/A
- EPS Growth
- TMQ N/A
- FDMT N/A
- EPS
- TMQ N/A
- FDMT N/A
- Revenue
- TMQ N/A
- FDMT $23,000.00
- Revenue This Year
- TMQ N/A
- FDMT $13,048.65
- Revenue Next Year
- TMQ N/A
- FDMT N/A
- P/E Ratio
- TMQ N/A
- FDMT N/A
- Revenue Growth
- TMQ N/A
- FDMT N/A
- 52 Week Low
- TMQ $0.47
- FDMT $2.24
- 52 Week High
- TMQ $2.09
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- TMQ 71.19
- FDMT 51.31
- Support Level
- TMQ $1.30
- FDMT $4.23
- Resistance Level
- TMQ $2.02
- FDMT $4.42
- Average True Range (ATR)
- TMQ 0.12
- FDMT 0.26
- MACD
- TMQ 0.05
- FDMT -0.00
- Stochastic Oscillator
- TMQ 65.97
- FDMT 58.54
About TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.